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ABSTRACT 
SYDNEY REBECCA HARRISON: Method Development and Pharmacokinetic Study of 
JY08, A Dual Opioid-NPFF Receptor Ligand 
(Under the direction of Dr. Bonnie A. Avery) 
Within the United States and worldwide, a rapidly developing public health crisis is at 
hand due to the abuse of opioids.  With high percentages of Americans experiencing both 
acute and chronic pain and limited treatment routes, opioid analgesics are highly 
prescribed in clinical practice.  These drugs act on central nervous system to activate 
opioid receptors in regions of the brain regulating pain and reward.  However, these 
compounds are associated with many unwanted adverse effects including tolerance, 
dependence, hyperalgesia, and addiction.  Thus, there is a need to for the development of 
new drug candidates that can serve as analgesics for long-term use without the unwanted 
side effects.  The neuropeptide FF (NPFF) system is known to modulate the anti-
nociceptive properties of the opioid system.  With this knowledge, the development of 
compounds that can serve both as a NPFF receptor antagonist and an opioid receptor 
agonist has become a recent focus in analgesic drug discovery and development.  The 
novel compound JY08 was designed as a dual-activity ligand that acts as an agonist at the 
mu-opioid receptor and antagonist at the NPFF receptor in order to combat the tolerance 
and hyperalgesia conditions commonly associated with long-term opioid use.  Ultra-high 
performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) 
bioanalytical methods were developed for the quantification of JY08 through 
pharmacokinetic, solubility, and metabolic stability studies. 
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1. INTRODUCTION 
1.1 The opioid epidemic 
The United States is currently in the midst of an ongoing opioid epidemic.  On October 
26, 2017, President Donald Trump declared the national opioid crisis as a public health 
emergency (1).  The US has experienced a 17-year increase in opioid overdose deaths 
due to both prescription and illicit opioids (2).  Weiner et al. identified three driving 
forces associated with the growing opioid epidemic: the moral imperative for providers to 
treat pain and relieve suffering, the under-treatment of pain, and pharmaceutical 
industries (3).  The epidemic’s antecedents can be traced back to the late 1990s during 
which the American Pain Society recognized pain as the fifth vital sign (4).  As a result of 
these efforts and the associated moral imperative, physicians became more liberal in the 
prescription of opioids for chronic, noncancer pain (4).  As pain was being adopted as the 
fifth vital sign, OxyContin was first hitting the markets.  It was soon to become top 30% 
of total analgesic sales and become the most abused prescription opioid on the market 
(4).  The manufacturer, Purdue Pharma, was assertively marketing OxyContin while 
distorting the risk for addiction associated with the drug (5).   Mass prescription of opioid 
analgesics for acute and chronic pain soon followed these events, contributing to much of 
the crisis currently being experienced in the United States. 
As the leading cause of US injury-related death, opioid overdoses were attributed to over 
42,000 deaths in 2016, five times higher than experienced in 1999 (6).  On average, 115 
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Americans die each day due to opioid abuse and misuse (2).  However, overdoses are not 
the only risk related to opioids; the abuse, misuse, and addiction related to these drugs are 
each hallmarks of the current epidemic.  In 2014, 2 million individuals claimed to abuse 
or be dependent on prescription opioids (7).  Additionally, over 1000 patients are treated 
each day in emergency departments for opioid misuse (8).  Coinciding with these 
increases in use, increases in the diagnosis of opioid-use disorder have been observed 
with 2.0 million people over the age of 12 years being affected in 2016 (9).  Factor in the 
increased risk of infectious disease due to unsafe injecting and other psychiatric 
comorbidities, the US is currently experiencing one of the greatest public health crises of 
its time.  The opioid crisis reaches beyond the United States, with 29.5 million people 
globally suffering drug use disorders—the majority of these due to opioids (10).   
Recently the National Institute of Health (NIH) has launched an initiative to address this 
public health crisis focusing on three areas: overdose-reversal interventions, treatments 
for opioid addiction, and non-addictive treatments for chronic pain (11).  With the 
majority of opioid abusers starting their path to dependence and addiction through 
prescription medications, the population that depends on opioid analgesics for daily 
living are particularly vulnerable in this epidemic.   
1.1.1 Chronic pain 
As defined by the International Association for the Study of Pain (IASP), pain is “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage or described in terms of such damage” (12). The IASP defines chronic pain as 
“pain that persists beyond normal tissue healing time, which is assumed to be three 
months” (12).  Chronic non-cancer pain is a multifactorial condition that can be attributed 
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to neuropathic pain, fibromyalgia, lumbar pain, osteoarthritis, and many others.  Chronic 
pain is reported to affect approximately 30% of Americans and 20% of people worldwide 
(11,13)  The condition is also the cause for 15-20% of physician visits (13).  The 
recommended first line of treatment for chronic pain includes antidepressants, 
anticonvulsants, and topical lidocaine (11).  The IASP recommends opioids as a second-
line chronic pain treatment (11).  However, the use of opioids for the treatment of chronic 
pain is very common, with an estimated 20% of patients presenting with pain or a pain-
related condition receiving an opioid prescription (14).  Long-term use of opioids has 
been associated with many adverse effects including gastrointestinal issues, addiction, 
tolerance, cardiovascular complications, and hyperalgesia.  Because of current treatment 
limitations and the US Congress declaration of 2000-2010 Decade of Pain and Control 
Research, the prescription of opioid analgesics for pain management has been rapidly 
rising in clinical practice.  Addressing the needs of patients with chronic pain through the 
development of safer, more effective treatments is a necessary step in ultimately 
overcoming the opioid crisis.  
1.2 The opioid system 
The opioid receptor system consists of three subtypes widely distributed throughout the 
CNS and PNS: mu, kappa, and delta.  Opioid medications primarily exert their analgesic 
effects through binding to the mu-opioid receptors (15).  Within the CNS, mu-opioid 
receptors are present at high concentrations in areas regulating nociception 
(periaqueductal gray, thalamus, cingulate cortex, and insula), pain-induced emotional 
response (amygdala), and reward pathways (ventral tegmental area and nucleus 
accumbens) (15).  Repeated use of opioids is known to be accompanied with an array of 
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unwanted adverse effects.  Tolerance is a primary effect of frequent opioid use.  
Continuous administration of opioid agonists leads to a suppression of endogenous 
opioids and decrease in analgesic efficacy.  This phenomenon is often observed in 
individuals with chronic pain disorders or opioid use disorders, two of the populations 
most dependent on opioid analgesics.  The physiological process of tolerance involves a 
reduction in endogenous opioid production in the body.  Thus, higher doses of exogenous 
opioids are needed with each subsequent administration in order to achieve the same 
analgesic effect, and for those suffering from opioid use disorder, often to reach the same 
euphoric effect.  Tolerance also involves the desensitization and internalization of opioid 
receptors, further decreasing agonist efficacy (16).  Opioid-induced hyperalgesia (OIH) 
has also been recognized as an issue due to long-term opioid use.  Though commonly 
confused with tolerance, OIH is a separate phenomenon associated with opioid use.  This 
disorder leads to an increased sensitivity to pain stimuli.  Thus, patients taking opioid 
analgesics for the treatment of pain will experience increasing pain sensations, resulting 
in the use of higher doses of opioids as with tolerance.  The mechanism of OIH is thought 
to be a counter-balance by endogenous pronociceptive peptides such as dynorphin A and 
neuropeptide FF.  Neuropeptide FF (NPFF) and its receptors have been found to play a 
role in pain transmission, interacting with the opioid system (17).  These anti-opioid 
modulating systems are observed to be overstimulated during chronic opioid 
administration.  Dual ligands for the opioid and NPFF receptors have recently become a 
target of drug discovery and design in the development of treatments for chronic pain 
without the classic opioid-related adverse effects. 
1.2.1 Neuropeptide FF 
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Neuropeptide FF belongs to the RF-amide peptide family and interacts with two Gi 
protein-coupled receptors, NPFFR1 and NPFFR2.  These receptors are distributed 
throughout the central nervous system (CNS) with high density in the spinal dorsal horn 
and the periaqueductal gray, areas involved in pain modulation (18).  The NPFF signaling 
system has is bimodal in pain perception, producing both pro-nociceptive and anti-
nociceptive effect (17).  The experienced effect is dependent upon the route of 
administration.  Intra-thecal administration of NPFF is shown to potentiate opioid 
analgesia.  In contrast, intra-cerebroventricular administration of NPFF is shown to 
decrease morphine-induced analgesia in rats (17).   
1.3 JY08, a novel dual NPFF/opioid receptor ligand 
JY08 was developed by the McCurdy research group at the University of Mississippi 
Department of BioMolecular Sciences.  The compound was developed to create a dual-
activity drug that acts as an analgesic while eliminating tolerance or hyperalgesic effects.  
JY08 is a non-peptide small-molecule with the classic guanidine and phenyl components 
of NPFF receptor antagonists.  Structure-activity relationship (SAR) studies analyzing the 
effect of NPFF’s C-terminal amino acids on NPFFR binding and activity have shown that 
the amidated residues of phenylalanine and arginine on NPFF are crucial for activation of 
anti-opioid effects (19).  Thus, the guanidine and phenyl groups on JY08 are able to 
mimic these interactions while maintaining low molecular weight and size to increase 
bioavailability.  Additionally, the absence of a peptide bond prevents protease cleavage of 
the NPFF antagonist.  A piperidine core was incorporated into the molecule based on past 
mu-opioid agonists developed by the McCurdy research group to facilitate opioid 
receptor binding.  Based on the structure and Lipinski’s parameters regarding oral 
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bioavailability, JY08 meets 3 of 4 criteria and is predicted to be orally bioavailable 
(Table 1).  The calculated LogP of JY08 also indicates the compound to have high 
lipophilicity, showing potential for JY08 to cross the blood brain barrier.  These 
predications are to be tested later through in vivo studies. 
 
 Lipinski’s Rules JY08 
Molecular weight  500 402.59 
Number of hydrogen bond donors  5 3 
Number of hydrogen bond acceptors  10 4 
Calculated LogP 0 < LogP < 5 5.305 
Table 1. Prediction of Oral Bioavailability 
JY08 was tested in multiple cell assays.  When tested against the delta-, kappa-, and mu-
opioid receptors, it exhibited a Ki of 1763  215, 649.9  117.8, and 34.29  5.38 nM, 
respectively.  JY08 also exhibited an EC50 of 721.6  195.0 nM for the mu-opioid 
receptor.   
Figure 1. Structure of JY08 
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1.4 Preclinical studies of JY08 
Pharmacokinetics and drug metabolism are essential components of the drug 
development process.  In order to successfully develop a drug candidate, the 
pharmacokinetic principles of absorption, distribution, metabolism, and elimination 
(ADME) must be analyzed.  Key parameters for pharmacokinetic analysis include oral 
bioavailability (F), half-life (t1/2), volume of distribution (Vd), and clearance (CL).  These 
screening processes can eliminate drug candidates that exhibit poor absorption, extensive 
first-pass metabolism, and/or too long/short half-lives.  However, these processes can 
also identify drug candidates that have good oral bioavailability and distribution to target 
tissues.  Thus, both in vitro and in vivo pre-clinical studies are necessary for the 
development of successful drug candidates for potential use in humans.   
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2. METHODS 
2.1 Materials and reagents 
The compound (JY08) and internal standards (WA475, CM398) were provided by Dr. 
Christopher McCurdy, initially synthesized by Dr. McCurdy’s research group, 
Department of BioMolecular Sciences, The University of Mississippi.  LC-MS grade 
methanol, acetonitrile, and water were purchased from Fisher Scientific (Fair Lawn, NJ, 
USA).  Formic acid and trifluoroacetic acid were obtained from Mallinckrodt Baker Inc. 
(Phillipsburg, NJ, USA).  TRIS, magnesium chloride, and potassium phosphate were 
obtained from Sigma-Aldrich (St. Louis, MO, USA).  NADPH was purchased from MP 
Biomedicals (Solon, OH, USA).  Rat liver microsomes were purchased from XenoTech 
(Lenexa, KS, USA).  Rat plasma was purchased from VWR (Suwannee, GA, USA).  
2.2 Instrumentation and analytical conditions 
Two LC-MS/MS instruments were used for analysis of the compounds.  The 
instrumentation from Thermo Scientific was used for the provided calibration curve, 
metabolic stability studies, and solubility studies.  Waters instrumentation was used for 
the analysis of pharmacokinetic studies in rats.  Separate methods for JY08 and the 
respective internal standards (IS) were developed on each instrument to ensure validated 
analysis.  Internal standards were chosen based on their chemical structure and function, 
which is preferably similar to the structure and function of JY08.  The IS should be 
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compatibile with the LC-MS/MS method developed for JY08 and produce strong, 
consistent signals within the run time. 
2.2.1 Method development on Thermo Scientific UPLC-MS/MS systems 
Accela ultra-high performance liquid chromatography system (Thermo Scientific, 
Waltham, MA, USA) equipped with a quaternary solvent manager, vacuum degasser, 
thermostatted column sleeve, an auto-sampler, a Waters Acquity UPLC CSH C18 
column (1.7 L, 2.1 x 100 mm; Milford, MA, USA)and was used for chromatographic 
separation.  The mobile phase was a gradient method (Table 2) using 0.02% v/v 
trifluoroacetic acid in water and 0.02% v/v trifluoroacetic acid methanol.  The mobile 
phase was pumped at a flow rate of 0.3 mL/min for a run time of 3.5 minutes.  The 
column temperature was maintained at 40oC and the injection volume was 10 L.  Two 
washes were used in between runs to prevent carryover and sample contamination: strong 
needle wash (methanol) and weak needle wash (50:50 methanol: water (0.01% v/v formic 
acid)).  Weak needle washes typically have similar compositions to the mobile phase and 
are used following the strong needle wash to ensure the strong wash is flushed from the 
needle and sample loop. 
Time (min) %A %B 
0 95 5 
2 5 95 
2.5 5 95 
3 95 5 
3.5 95 5 
Table 2. UPLC-MS/MS Gradient 1   *A- 0.02% TFA in Water *B-0.02% TFA in Methanol 
Mass spectrometric (MS) analysis was performed using TSQ Quantum Access MAX 
(Thermo Scientific, Waltham, MA, USA) equipped with an electro-spray ionization (ESI) 
source. The detection was achieved with ESI positive ionization using multiple reaction 
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monitoring (MRM).  The protonated parent ion [M + H]+ and daughter ions were 
monitored for transitions m/z 403.22 > 268.27 and 403.22 > 224.97.  WA475, internal 
standard, was monitored for transition m/z 406.23 > 161.08.  The MS parameters were 
tuned to optimize the molecular ion signal.  Spray voltage, tube lens offset, and skimmer 
offset were set at 3500, 127, and 0 V.  Sheath gas pressure, ion sweep gas pressure, and 
aux gas pressure were optimized to 40, 0, and 5 psi, respectively.  Capillary temperature 
was set to 325C.   
2.2.2 Method development on Waters UPLC-MS/MS systems 
Chromatographic separations were carried out on Acquity ultra-high performance liquid 
chromatography system (Waters, Milford, MA, USA) equipped with a binary solvent 
manager, vacuum degasser, thermostatted column compartment and an auto-sampler.  A 
Waters Acquity UPLC CSH C18 column (1.7 L, 2.1 x 100 mm; Milford, MA, USA) 
was used for chromatographic separations.  A gradient method (Table 1) using aqueous 
ammonium formate buffer (5 mM, 0.25% v/v formic acid) and acetonitrile was applied 
for chromatographic separation.   The mobile phase was pumped at a flow rate of 0.28 
mL/min for a run time of 4.0 minutes.  The column temperature was maintained at 40oC 
and the sample temperature was maintained at 10oC.  Injection volume was 2 L.  Two 
washes were used in between runs: strong needle wash (80:20 acetonitrile: water) and 
weak needle wash (20:80 acetonitrile: water).   
Time (min) % A % B Curve 
0 90 10 0 
0.8 90 10 6 
2.2 5 95 6 
3.2 5 95 6 
3.4 95 5 6 
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4.0 95 5 6 
Table 3.UP LC-MS/MS Gradient 2  *A- ammonium formate buffer (5 mM, 0.25% formic acid v/v) *B- acetonitrile 
Mass spectrometric analysis was performed using Xevo TQ-S Micro (Waters, Milford, 
MA, USA) equipped with an ESI source.  The detection was achieved with ESI positive 
ionization using multiple reaction monitoring.  The protonated parent ion [M + H]+ and 
daughter ions were monitored for transitions m/z 403.20 > 268.15 and 403.22 > 225.04.  
CM398 was used as an internal standard for all analyses on Waters instrumentation due 
to better signals and method compatibility.  IS was monitored for transition m/z 396.14 > 
232.10.  The following MS parameters were tuned for optimization of the signal.  
Capillary voltage was set to 0.5 kV.  Source temperature and desolvation temperature 
were set to 150 and 500C, respectively.  Cone gas flow and desolvation gas flow were 
set to 50 and 900 L/h, respectively. 
2.3 Preparation of calibration standards  
Initial stock solution of JY08 and IS (WA475, CM398) were prepared in methanol to 
yield concentrations of 1 mg/mL.  Appropriate volumes of stock solutions were serially 
diluted with methanol to obtain working standard solutions of JY08 and IS ranging from 
20 to 4000 ng/mL.  The working standard solutions were stored at -20oC.   
For calibration standards, samples at 1, 2.5, 10, 50, 100, and 190 ng/mL were prepared by 
2 L of the appropriate stock to 198 L of 2:1 0.02% v/v TFA in methanol: 0.02% v/v 
TFA in water containing IS (3 ng/mL) for a total volume of 200 L. 
For pharmacokinetic sample analysis, calibration standard samples at concentrations of 1, 
2.5, 5, 25, 50, 100, 190 and 200 ng/mL were prepared by spiking 1 L of the appropriate 
stock to 19 L of rat plasma. 
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2.4 Plasma sample clean-up 
The rat plasma samples were stored after collection at -80oC and thawed at room 
temperature prior to analysis.  Protein precipitation with acetonitrile containing the IS 
(CM398, 20 ng/mL) and formic acid (0.25% v/v) was used for the extraction of JY08 
from rat plasma samples.  An aliquot of 20 L of plasma was quenched with 100 L of 
quenching solution.  Samples were vortexed for 10 minutes at 2000 rpm on a 
BenchMixer multi-tube vortex mixer (Benchmark, San Fransisco, CA, USA).  Samples 
were then centrifuged at 4C for 10 minutes at 15000 rpm using Eppendorf centrifuge 
5427-R (Eppendorf, Hauppauge, NY, USA).  A fixed aliquot (~80 L) of the supernatant 
was then taken from centrifuged samples for analysis via UPLC-MS/MS.   
2.5 Solubility studies 
The most common route of administration for drugs is oral ingestion (20).  Oral 
bioavailability is dependent on several factors including aqueous solubility, dissolution, 
and first-pass metabolism (20).  Thus, solubility studies are utilized to determine if 
compounds are sufficient candidates for oral administration by examining the aqueous 
solubility at physiological pH. 
Solubility of JY08 was determined in phosphate buffer at a pH of 7.4 (n=2).  Stock 
solution of JY08 13 mg/mL was made fresh in potassium phosphate buffer (0.1 M, pH 
7.4, 100 L).  Samples were placed on a tube revolver for 24 hours at room temperature 
(25C).  After 24 h, samples were centrifuged and the supernatant was collected.  This 
supernatant was then diluted three times.  For a dilution factor of 1000, supernatant (2 
L) was added to methanol (1998 L).  For a dilution of factor of 50,000, 10 L of the 
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first dilution was added to methanol (490 L).  For a dilution factor of 500,000, 10 L of 
the second dilution was added to 90 L of methanol.  Each sample was then analyzed via 
UPLC-MS/MS for JY08 content. 
2.6 Metabolic stability studies 
Metabolic stability studies are important for the in vitro analysis of a drug’s 
pharmacokinetic parameters.  The liver is a primary site of drug metabolism (21).  High 
rates of metabolism can impact the oral bioavailability of a drug, while low rates can 
impact toxicity.  Metabolism in the human body primarily occurs through two phases.  
Phase I modifications (hydrolysis, oxidations, reductions, etc.) are most commonly 
performed by the cytochrome P450 enzymes.  Phase II modifications involve conjugation 
reactions performed by transferases.  Phase I metabolic stability studies were conducted 
on JY08 using rat liver CYP450 microsomes.  Metoprolol, a compound with a well-
defined metabolic profile, was used for positive and negative control samples. 
To a 96-well plate, rat liver microsomes (0.5 mg/mL, 10 L) were added.  TRIS buffer 
(50 mM, pH 7.4, 168 L) was then added, followed by magnesium chloride in TRIS (500 
mM, 20 L).  NADPH (40 mM, 20 L) was added to positive controls and JY08 sample 
only.  The 96-well plate was then placed in an incubator held at 37C for 10 minutes.  
See procedure below for specific reaction mixture.   
For negative and positive control samples, metoprolol (1M, 2 L) was added to the 
specified wells and placed back in the incubator.  For JY08 sample, JY08 (1 M, 2 L) 
was then added to the specified wells and placed back in the incubator.  At the designated 
time points of 0, 5, 10, 15, and 20 minutes, aliquots of 40 L were taken from each 
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reaction mixture and placed in a separate 96-well plate containing a quenching solution 
of ice-cold methanol with IS (3 ng/mL WA475).  Samples were then centrifuged at 
12000 rpm for 15 minutes.  The supernatant (50 L) was collected and added to 100 L 
of 0.02% v/v TFA in water for analysis via LC-MS. 
2.7 Pilot pharmacokinetic study of JY08 in rats 
Pharmacokinetic animal studies were performed using cannulated, male Sprague-Dawley 
rats (n=2) obtained from Envigo (East Millstone, NJ, USA) with an average body weight 
of 240.5  12 g.   All experimental procedures were approved and performed in 
accordance with the guidelines set in place by the Institutional Animal Care and Use 
Committee (IACUC) of the University of Mississippi.  The rats were housed in metabolic 
cages and allowed free movement and access to water throughout the experiment.  Rats 
were fasted 12-15 hours prior to the experiment.  For pilot studies, both single oral dosing 
(20 mg/kg) and IV bolus (1 mg/kg) of JY08 (n=1, each) was tested.    The oral dose was 
prepared by dissolving JY08 (41.3 mg) in distilled water (7 mL) and administered as a 
weight-based dose using an oral gavage syringe.  IV bolus dose was prepared by 
dissolving JY08 (3 mg) in saline (3 mL) and injected through the caudal vein.  Sample 
collection for IV was performed at pre-dose and 5 min, 10 min, 20 min, 30 min, 45 min, 
1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h post-dose.  For oral pharmacokinetic study, blood 
samples were collected pre-dose and 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 
and 24 h post-dose. At each time point, 0.1 mL of blood was taken from each animal 
using a fresh syringe.  Following each collection, cannulas were flushed with 0.1 mL of 
heparinized saline.  Blood samples were collected in micro-centrifuged tubes and 
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centrifuged for 10 minutes to separate plasma and cell components.  Plasma was then 
placed into a clean tube and stored at -80C until analyzed. 
2.8 Full pharmacokinetic study of JY08 in rats 
Pharmacokinetic animal studies were performed using cannulated, male Sprague-Dawley 
rats received from Envigo (East Millstone, NJ, USA) with an average body weight of 275 
 25 g.  All experimental procedures were approved and performed in accordance with 
the guidelines set in place by the Institutional Animal Care and Use Committee (IACUC) 
of the University of Florida.  The rats were housed in metabolic cages and allowed free 
movement and access to water throughout the experiment.  Rats were fasted 15 hours 
prior to the experiment.  Male rats received either a single oral (n=6) or IV (n=6) 
administration of the JY08 formulation.  The oral dose was administered using an oral 
gavage syringe.  IV bolus was administered through the caudal vein.  Sample collection 
following single IV bolus (1 mg/kg) was performed pre-dose and 5 min, 10 min, 15 min, 
20 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, and 36 h post-dose.  
Sample collection following oral dosing was performed pre-dose and 5 min, 10 min, 15 
min, 20 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose.  Please note that 
blood volume taken from each animal did not exceed 10% of the total blood volume for 
each animal.  At each time point, approximately 0.1 mL of blood was sampled from each 
animal using a fresh syringe.  Following each collection, cannulas were flushed with 0.1 
mL of heparinized saline.  Blood samples were collected in micro-centrifuged tubes and 
centrifuged for 10 minutes to separate plasma and cell components.  Plasma was then 
collected and stored at -80C until analyzed. 
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2.9 Pharmacokinetic analysis 
Data analysis of pharmacokinetic studies was performed with Phoenix Software (Certara 
Inc., MO, USA) using non-compartmental analysis.  Concentration-time data and 
pharmacokinetic parameters are represented as mean  standard error mean (SEM).  Peak 
plasma concentration (Cmax) and time to reach peak concentration (Tmax) were determined 
based on concentration-time data.  Area under the plasma concentration-time curve from 
0 to last measured concentration (AUClast) was calculated through the linear trapezoidal 
method.  Half-life (t1/2) was calculated as a function of the slope (elimination constant) 
from the plotted curves.   
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3. RESULTS AND DISCUSSION 
3.1 UPLC-MS/MS optimization 
3.1.1 Thermo Scientific 
Positive electrospray ionization of JY08 and WA475 produced their respective molecular 
ions [M + H+] at m/z 403.22 and 406.23.  Capillary voltage (3.5 kV), tube lens offset (127 
V), capillary temperature (325 oC) and sheath gas pressure (40 psi) were tuned to obtain 
the most intense signal for both compounds.  Fragmentation produced several daughter 
ions for JY08 and IS, establishing qualitative and quantitative ions for monitoring 
transitions.   
Compound Ions Dwell 
(sec) 
Cone 
Voltage 
Collison 
Energy 
Voltage 
JY08- Qualitative 403.22 > 268.27 0.21 88.0 25.0 
JY08- Quantitative 403.22 > 224.97 0.21 88.0 28.0 
WA475- IS 406.23 > 161.08 0.21 70.0 34.0 
Table 4. MS Parameters for JY08 and WA475 
During chromatographic method development, both isocratic and gradient methods were 
explored with the intent to develop a quick, efficient method with optimal retention times 
and peak shapes for both JY08 and IS.  Various chromatographic conditions were 
employed using multiple columns (Acquity UPLC BEH C18, CSH C18, Cyano, Phenyl 
Hexyl) and mobile phase compositions (methanol, acetonitrile, formic acid, and 
ammonium acetate buffer) in both gradient and isocratic methods.  It was determined that 
an Acquity UPLC CSH C18 column and a gradient mobile phase of 0.1% v/v formic acid 
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in water and methanol optimized the chromatographic separation of both JY08 and 
WA475 (IS).  Retention times for JY08 and WA475 were 2.40 and 2.65 minutes, 
respectively.  This method produced sharp, clean peaks allowing for a LOD of 1 ng/mL. 
3.1.2 Waters  
The electrospray ionization of JY08 and the IS produced their respective protonated 
molecular ions, [M + H]+, at m/z 403.20 and 396.14 under positive ionization mode.  To 
obtain the most intense molecular ion signal, several source parameters were optimized.  
These include capillary voltage (0.5 kV), source temperature (150oC), desolvation 
temperature (500oC), cone gas flow (50 L/hr), and desolvation gas flow (900 L/hr).  The 
protonated molecular ions of each compound undergo fragmentation in the collision cell 
of the mass spectrometer.  Several daughter ions are produced from each compound and 
those with the greatest abundance and stability are selected for monitoring transitions.  
Fragment ions m/z 268.15 and m/z 225.04 were selected as the qualitative and 
quantitative transitions for JY08, respectively.  Fragment ion m/z 232.10 of the IS was 
selected.  Several parameters were optimized to both compounds and their fragment ions 
as described below in Table 5.   
Compound Ions Dwell 
(sec) 
Cone 
Voltage 
Collison 
Energy 
Voltage 
JY08- Qualitative 403.20 > 268.15 0.110 88.0 28.0 
JY08- Quantitative 403.20 > 225.04 0.110 88.0 28.0 
CM398- IS 396.14 > 232.10 0.110 70.0 26.0 
Table 5. MS Parameters for JY08 and CM398 
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Figure 2. MRM spectra of (A) JY08 and (B) internal standard CM398. 
Chromatographic analysis of JY08 and the IS was initiated with the intent to develop a 
simple method with clean separation in a short run time.  Various chromatographic 
conditions were tested using various columns (Acquity UPLC CSH and BEH C18) and 
mobile phase compositions (methanol, acetonitrile, formic acid, ammonium acetate, and 
ammonium formate buffers) in both gradient and isocratic methods.  It was determined 
that an Acquity UPLC CSH C18 column and a gradient mobile phase of 0.25% formic 
acid in 5 mM ammonium formate buffer and acetonitrile optimized the chromatographic 
separation of both JY08 and the IS.  Retention times for JY08 and CM398 were 1.87 and 
1.91 minutes, respectively.  This method produced sharp, clean peaks allowing for a LOD 
of 1 ng/mL.   
A 
B 
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Figure 2. Representative MRM Chromatograms of (A) JY08 Quantifier Ion (B) JY08 Qualifier Ion (C) CM398  
3.2 Calibration curve 
Calibration standards 1, 2.5, 5, 25, 50, 100, 190 and 200 ng/mL were run using UPLC-
MS Gradient 1 (Table 3).  Calibration curve was constructed by plotting the peak area 
ratio of JY08 to that of IS against the corresponding nominal concentration. The linear 
regression equation of the calibration curve obtained from 8 points was y = 0.0785x + 
0.0183.  Correlation coefficient was always ≥0.99 during the analysis. 
 
Graph 1. JY08 Calibration Curve in Rat Plasma 
3.3 Solubility studies 
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The calculated solubility of JY08 at a pH of 7.4 is 3.75 mg/mL.  The United States 
Pharmacopeia states that a substance is “slightly soluble” if 100-1000 parts of solvent are 
required to dissolve 1 part of solute (20).  Thus, JY08 can be classified as slightly 
soluble.  These values indicate JY08 partly in an ionized state at pH 7.4.  The extent of 
ionization of a drug will determine the amount of absorption at a given pH within the 
body.  Thus, at a physiological pH of 7.4, only unionized drug will be absorbed. 
3.4 Metabolic stability studies 
Metabolic stability samples were run on Thermo Scientific instrumentation using gradient 
method 1.  The area under the curve (AUC) of each sample was used to calculate the 
percent remaining of each compound, using the IS (WA475) AUC as reference.  The 
JY08 sample exhibited odd metabolism patterns, with an increase in concentration for 
three time points.  This is most likely due to instrumentation or procedure error.  
However, repeated studies (not shown) displayed the same metabolic pattern.  This 
metabolic pattern may indicate a slow metabolism of JY08 by CYP450 enzymes or 
primary metabolism of JY08 occurs by phase II enzymes.  Positive control metoprolol 
sample exhibited a normal metabolism pattern, indicating that reaction components and 
enzymes were working properly.  Negative control metoprolol sample was expected to 
stay at 100% throughout all time points; however, the decreases in concentration 
observed can be attributed to non-specific binding of compound to enzyme.  Because of 
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the problems that occurred with this study, the phase I metabolic studies will be repeated 
by the Avery group at a later date. 
 
Graph 2. Phase I Metabolic Stability of JY08 
 
Time (minutes) % remaining 
JY08 
% remaining 
Metoprolol (NC) 
% remaining 
Metoprolol (PC) 
0 100 100 100 
5 118.30 84.80 59.39 
10 137.75 79.92 44.12 
15 121.75 81.54 41.25 
20 92.32 78.88 38.66 
Table 6. Measured Metabolism in Rat Liver Microsomes 
3.5 Pilot pharmacokinetic study 
Following IV dosing in Sprague Dawley rats (n=1), JY08 exhibited biphasic and 
extravascular distribution with a volume of distribution (Vd) of 26.3 L/kg.  This volume 
of distribution is larger than the total blood volume in rats (0.085 L/kg) (22).  IV 
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injections follow multiphasic absorption patterns in which there are two phases.  In the 
alpha phase, drug distribution shifts from systemic circulation (central compartment) to 
body tissues and organs (peripheral compartment).  In the alpha phase, absorption is 
greater than elimination.  In the beta phase, elimination is greater than absorption and a 
decrease in plasma drug concentration is seen due to metabolism and excretion 
mechanisms.  Extra-hepatic metabolism and elimination was determined to be negligible 
with a clearance (CL) of 2.0 L/h/kg compared to average hepatic blood flow of 4.8 
L/h/kg in rats (23).   
The rat receiving an oral dose of JY08 (n=1) also displayed extensive extravascular 
distribution as indicated with a calculated Vd of 26.3 L/kg.  The study also displayed 
quick absorption, distribution, and elimination of JY08 from plasma and an oral 
bioavailability of 13.9%.  The concentration-time curves resulting from the oral 
pharmacokinetic study of JY08 display multiple peak phenomenon (Graph 3).  Oral 
concentration-time curves typically exhibit an initial absorption phase in which an 
increase in concentration is seen following administration as the drug enters systemic 
circulation.  Multiple peaks in the curve may indicate multiple absorption phases of the 
compound occurring in the animal.  Multiple peak phenomenon can be due to 
enterohepatic recirculation, gastrointestinal recirculation, delayed gastric emptying, 
and/or absorption differences in the intestines (24).  Since multiple peaks are not apparent 
in the IV concentration-time curve, enterohepatic circulation is probably not the cause of 
the multiple absorption phases.  This phenomenon could possibly be due to the multiple 
pKa points displayed by JY08.  Drugs are only absorbed in unionized states.  Thus, as the 
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surrounding pH changes throughout the GIT, JY08 will experience different ionization 
states causing discontinuous absorption.   
After oral and IV dosing, mean residence time (MRT) for JY08 was found to be 6.4 and 
4.9 h, respectively.  MRT is used to represent the average amount of time the drug stays 
in a body.  Since drugs administered intravenously do not undergo an absorption phase, it 
is expected for the residence time of IV administered drugs to be shorter than oral drugs.  
This concept applies to terminal half-life (t1/2) as well (25). 
Parameters Oral Intravenous 
Cmax1 (ng/mL) 174.9 - 
Cmax2 (ng/mL) 158.4 - 
Tmax1 (h) 0.5 - 
Tmax2 (h) 2.0 0 
AUC (ng•h/mL) 1357.5 489.5 
MRT (h) 6.4 4.9 
T1/2  (h) 11.33 8.93 
Vd (L/kg) 34.1 26.3 
Clearance (L/h/kg) 2.1 2.0 
Bioavailability (%) 13.9 - 
Table 7. Pharmacokinetic Parameters of JY08 Pilot Study 
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3.6 Full pharmacokinetic study 
The full PK studies of JY08 in rats produced similar results to pilot studies.  With a 
volume of distribution (Vd) of 20.4  4.3 and 32.8  6.8 L/kg for oral and IV doses, 
respectively, JY08 is extensively distributed in extra-vascular systems.  Extra-hepatic 
metabolism and elimination were negligible with clearances (CL) of 1.1  0.2 and 1.2  
0.2 L/h/kg for oral and IV, respectively.  Similar to pilot study results, oral bioavailability 
was determined to be low at 9.1%.  This low range may be due to first pass metabolism 
or poor absorption of JY08 in the gastrointestinal tract (25).  Concentration-time curves 
of the oral pharmacokinetic study of JY08 display multiple peak phenomenon as also 
seen in the pilot study.  The Cmax and Tmax for each absorption phase is listed in Table 8.   
The terminal half-life for oral and IV doses was 13.6  2.7 and 32.8  6.8, respectively.   
Parameters Oral Intravenous 
Cmax1 (ng/mL) 217.5  40.0 - 
Graph 3. Pilot Oral Pharmacokinetic Study of JY08 Graph 4. Pilot IV Pharmacokinetic Study of JY08 
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Cmax2 (ng/mL) 210.1  36.1 - 
Tmax1 (h) 0.4  0.1 - 
Tmax2 (h) 2.8  0.6 - 
AUC (ng•h/mL) 1788.5  265.1 988.1  158.3 
T1/2 (h) 13.6  2.7 21.6  3.7 
Vd (L/kg) 20.4  4.3 32.8  6.8 
Clearance (L/h/kg) 1.1  0.2 1.2  0.2 
Bioavailability (%) 9.1 - 
Table 8. Pharmacokinetic Parameters of JY08 Full Study 
 
3.7 Putative metabolites of JY08 
Using MetaboLynx software, metabolites of JY08 from in vivo plasma samples were 
identified via mass spectrometry.  Phase I metabolism includes oxidation, reduction, 
hydrolysis, and dealkylation.  As depicted in Figure X, both metabolites 1 and 3 
underwent dealkylation reactions by phase I enzymes.  Metabolite 4 underwent a 
hydroxylation reaction.  In metabolite 2, the guanidine group of JY08 was cleaved.  Other 
metabolites that are conjugation products were also present in lower abundance.  
Graph 5. Oral Pharmacokinetic Study of JY08 Graph 6. IV Pharmacokinetic Study of JY08 
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Analyzing the possible biotransformation routes of JY08 can reveal metabolic “weak 
spots” in compound structure that can be modified through drug design to develop a more 
successful drug in vivo.   
 
Figure 3. Putative Metabolites of JY08 
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4. CONCLUSION 
With the rapidly evolving opioid crisis and limited long-term analgesic therapies, there is 
a major need for the development of opioids that can combat the tolerance and 
hyperalgesia commonly experienced with long-term use of opioids.  JY08, developed as a 
dual activity ligand at the mu-opioid receptor and neuropeptide FF receptor, has the 
potential to serve as a safer, more effective treatment for pain.   
The pharmacokinetic principles of absorption, distribution, metabolism, and excretion 
were analyzed to determine the physiochemical properties of JY08 in vitro and in vivo.  A 
simple and sensitive UPLC-MS method was developed for the analysis of these studies.  
A simple and efficient extraction method was developed for plasma sample preparation 
that required low plasma volumes, enabling repeated sampling in rodents.   
The results of ADME studies determined that JY08 is quickly absorbed in rats.  Single 
dose oral and IV pharmacokinetic studies revealed extensive extravascular distribution.  
In vitro metabolic studies were inconclusive but can be repeated to determine the primary 
pathway of metabolism of JY08.  In vivo studies showed that JY08 is primarily 
dependent on hepatic elimination.  When JY08 is dosed orally in rats, it exhibits multiple 
absorption phases and low oral bioavailability, most likely due to first pass effect or poor 
absorption.  Though bioavailability is low, the pharmacokinetic profile of JY08 with a 
large volume of distribution and long half-life support the potential of JY08 as a drug 
candidate for the treatment of pain in the clinical setting. 
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